Bioproduction, characterization, and evaluation of the biological activities of prodigiosin from Serratia marcescens HMS.

Hadeer O Jaheen, Hoda H Yusef, Soraya A Sabry, Mona E M Mabrouk

Abstract read

In one paragraph

Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hadeer O JaheenBotany and Microbiology Department, Faculty of Science, Alexandria University, Alexandria, Egypt. JaheenHadeer@gmail.com.ORCID http://orcid.org/0009-0003-6714-6581

Hoda H YusefBotany and Microbiology Department, Faculty of Science, Alexandria University, Alexandria, Egypt.ORCID http://orcid.org/0000-0001-8388-7089

Soraya A SabryBotany and Microbiology Department, Faculty of Science, Alexandria University, Alexandria, Egypt.

Mona E M MabroukBotany and Microbiology Department, Faculty of Science, Damanhour University, Damanhour, Egypt.ORCID http://orcid.org/0000-0002-9290-6816

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prodigiosin is a bioactive red pigment with antimicrobial and anticancer properties, offering a natural substitute for synthetic colorants. A pigment-producing strain, Serratia marcescens HMS, was isolated from air and identified via 16S rRNA sequencing (GenBank Accession No. PP456732.1; 100% similarity). Acetone yielded the highest pigment extraction efficiency (4.54 mg/L). Optimal production (6.98 mg/L) occurred in LB medium (pH 7) at 30 °C under shaking conditions (150 rpm). Sweet potato peels served as an effective low-cost and sustainable agricultural waste substrate for extracellular pigment production. The purified pigment was confirmed as prodigiosin using TLC, HPLC, FTIR, and GC–MS (C20H25N3O; m/z 323). The pigment displayed antimicrobial activity against Bacillus subtilis (inhibition zone: 12 mm), cytotoxicity against HepG2 and MCF-7 cells (IC50: 61.12 ± 2.64 and 87.86 ± 4.18 μg/mL, respectively), and α-glucosidase inhibitory activity (IC50: 380.27 ± 8.15 μg/mL). These results establish S. marcescens HMS as an efficient prodigiosin producer and highlight the pigment’s potential for pharmaceutical and industrial applications.

Indexed as

ProdigiosinSerratia marcescensAnti-Bacterial AgentsAntineoplastic AgentsBacillus subtilisGas Chromatography-Mass SpectrometryGlycoside Hydrolase InhibitorsHep G2 CellsHumansHydrogen-Ion ConcentrationMCF-7 CellsMicrobial Sensitivity TestsPhylogenyPigments, BiologicalRNA, Ribosomal, 16SAnti-Bacterial AgentsAntineoplastic AgentsGlycoside Hydrolase InhibitorsPigments, BiologicalProdigiosinRNA, Ribosomal, 16SBioactivity evaluationBioprocess optimizationCharacterizationIntracellular and extracellular prodigiosinSerratia marcescensSustainable production

Identifiers

PMID42032364

DOI10.1007/s11274-026-04936-8

PMCPMC13109127

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.